Navigation Links
Neurologix Announces First Quarter 2011 Financial Results
Date:5/13/2011

ble future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At March 31, 2011, the Company had cash and cash equivalents of approximately $5.4 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan of operations after October 31, 2011 and to repay the promissory notes issued in 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Neurologix Completes Additional $7 Million Financing
    5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... , Aug. 27, 2014  After the February 2014 ... Injury billing solution for medical practices and management ... toward the new software. "The feedback has ... Thompson . "The sheer number of demos and new ... need was for these types of software features." ...
    (Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
    (Date:8/26/2014)... -- Intelomed is pleased to announce that Mary ... the Vice President of Clinical Affairs. With over 30 ... industry, Kay,s experience in taking medical technology and associated ... global expansion, is a valuable addition to the Intelomed ... our team, and I am confident her focused and ...
    Breaking Medicine Technology:Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2
    (Date:8/27/2014)... Angeles, CA (PRWEB) August 27, 2014 Jaha ... To do this, Jaha invested in creating the industry’s most ... by adding functions that no other apps possess. ... a tracker that differentiates in three simple steps: locate, challenge ... launch on Tuesday, Aug 26, 2014 to garner support and ...
    (Date:8/27/2014)... Nava Beauty Store and Spa aims to ... from those seeking luxury care products to the everyday person ... end luxurious brands like Valmont and Elemis to cater to ... like Dermalogica and Bliss to provide easy to use and ... offer purely organic skin care products such as Jurlique, Rahua ...
    (Date:8/27/2014)... (PRWEB) August 27, 2014 Many patients ... reality is that depression has a mortality rate of ... bi-polar disorder is slightly less, though it's offset by ... 7%. In order to properly treat and manage ... bi-polar, medication must be taken as directed. Missed ...
    (Date:8/27/2014)... Australia (PRWEB) August 27, 2014 ... erratic climatic conditions and fluctuations in global supply and ... the past five years. The industry derives a large ... are subject to global market dynamics, with supply and ... Brazil and India. A strong Australian dollar for the ...
    (Date:8/27/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND REGENERATIVE PRODUCTS , the global market for advanced ... by 2014-end to $42.2 billion by 2019, with a ... to 2019. New technologies and an increasingly older population ... market. , While there are many conventional and generally ...
    Breaking Medicine News(10 mins):Health News:Jaha, Inc. The Most Affordable Fitness Band in the Market Released on Kickstarter 2Health News:Nava Beauty Store Announce Grand Opening in Great Neck, New York 2Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 3
    ... , CHICAGO, Aug. 17 A team ... Carol Associates Public Relations, of Fredericksburg, VA, is researching web sites ... found that in just one group of 30 sites researched, there ... , "These are omissions that are definitely narrowing ...
    ... EVANSTON, Ill. --- Anyone with an MP3 device -- just about every ... a notion of the majesty of music, of the primal place it ... be seen simply as stuff of the soul -- a frill that ... Northwestern University study. The study shows that musicians -- trained ...
    ... , , , ... Inc. (Nasdaq: RELV ), a nutrition and direct ... Relivables(TM) to complement the company,s line of proprietary nutritional supplements. ... Relivables product lineup is Reliv,s breakthrough r(TM) skincare collection that ...
    ... , , NEW YORK, Aug. ... of lifestyle media and fitness accessories, today announced that it will produce ... Bertinelli and her personal trainer, Christopher Lane. Complementing her successful weight loss ... out with Christopher in her living room, just like countless other women ...
    ... Brazilian Pharmacy Association Honors USP,s Roger Williams ... In recognition of a long-term commitment to advancing public health, ... or ANF) has awarded Roger L. Williams, M.D., the distinction ... of the U.S. Pharmacopeial (USP) Convention, a scientific nonprofit organization ...
    ... , , , Letter signed ... up" , , NEW YORK, Aug. 17 ... unprecedented joint call for prevention measures to be central to the reform ... letter released today , leaders at The California Endowment, The ...
    Cached Medicine News:Health News:Agency Provides Free Web Site Review 2Health News:Taking up music so you can hear 2Health News:Taking up music so you can hear 3Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 2Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 3Health News:Gaiam Announces New Deal With Valerie Bertinelli 2Health News:Lifetime Commitment to Public Health Recognized 2Health News:Leading Health Foundations Say Prevention is Vital to Health Systems Reform 2Health News:Leading Health Foundations Say Prevention is Vital to Health Systems Reform 3Health News:Leading Health Foundations Say Prevention is Vital to Health Systems Reform 4
    The playful pattern of this lens features sky-blue forms fanning out from the center of your eye....
    This design features a solid red iris....
    Tempting and mesmerizing Jaguar features a narrow black slit surrounded by reflective metallic teal....
    Maumenee vitreous aspirating cannula, 18 gauge....
    Medicine Products: